The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Open accessAbstract
Cutaneous melanoma is the most common skin cancer with an incidence that has been rapidly increasing in the past decades. Melanomas are among the most immunogenic tumors and, as such, have the greatest potential to respond favorably to immunotherapy. However, like many cancers, melanomas acquire various suppressive mechanisms, which generally act in concert, to escape innate and adaptive immune detection and destruction. Intense research into the cellular and molecular events associated with melanomagenesis, which ultimately lead to immune suppression, has resulted in the discovery of new therapeutic targets and synergistic combinations of immunotherapy, targeted therapy and chemotherapy. Tremendous effort to determine efficacy of single and combination therapies in pre-clinical and clinical phase I-III trials has led to FDA-approval of several immunotherapeutic agents that could potentially be beneficial for aggressive, highly refractory, advanced and metastatic melanomas. The increasing availability of approved combination therapies for melanoma and more rapid assessment of patient tumors has increased the feasibility of personalized treatment to overcome patient and tumor heterogeneity and to achieve greater clinical benefit. Here, we review the evolution of the immune system during melanomagenesis, mechanisms exploited by melanoma to suppress anti-tumor immunity and methods that have been developed to restore immunity. We emphasize that an effective therapeutic strategy will require coordinate activation of tumor-specific immunity as well as increased recognition and accessibility of melanoma cells in primary tumors and distal metastases. This review integrates available knowledge on melanoma-specific immunity, molecular signaling pathways and molecular targeting strategies that could be utilized to envision therapeutics with broader application and greater efficacy for early stage and advanced metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., & Hayday, A. C. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,004
COLEY, W. B. (1991) · PubMed · Cited by 965
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 1×
“For example, in early dysfunction, T cells showed low expression of CD38, CD101, CD30L and high expression of CD5, while late dysfunction is characterized by the opposite pattern (102).”
BackgroundCancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Jacobs, S. R., Herman, C. E., MacIver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., & Rathmell, J. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4476 · Cited by 850
Carr, E. L., Kelman, A., Wu, G. S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A. M., & Frauwirth, K. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903586 · Cited by 830
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression
Gottfried, E., Kunz-Schughart, L. A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A., & Kreutz, M. (2006) · Blood · doi:10.1182/blood-2005-05-1795 · Cited by 729
The PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · cited 2×
“, Egr1, Batf, Blimp, Lag3, Ctla4) (101).”
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699
Viguier, M., Lemaître, F., Verola, O., Cho, M.-S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., & Ferradini, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1444 · Cited by 686
Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593
L-arginine metabolism in myeloid cells controls T-lymphocyte functions
Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M., & Zanovello, P. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00132-7 · Cited by 592
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S., & Weiss, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37223 · Cited by 564
cGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Wieckowski, E. U., Visus, C., Szajnik, M., Szczepanski, M. J., Storkus, W. J., & Whiteside, T. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900970 · Cited by 560
Origin and development of dendritic cells
Liu, K., & Nussenzweig, M. C. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00879.x · Cited by 543
Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., Overberg, P., Rose, I., Basu, G. D., Vranic, S., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0654 · Cited by 522
Muul, L. M., Spiess, P. J., Director, E. P., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.989 · Cited by 486
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 482
Singhal, S., Bhojnagarwala, P. S., O'Brien, S., Moon, E. K., Garfall, A. L., Rao, A. S., Quatromoni, J. G., Stephen, T. L., Litzky, L., Deshpande, C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.001 · Cited by 478
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 461
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
The determinants of tumour immunogenicity
Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3246 · Cited by 441
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Type IIFN s induce anti‐tumor polarization of tumor associated neutrophils in mice and human
Andzinski, L., Kasnitz, N., Stahnke, S., Wu, C., Gereke, M., von Köckritz‐Blickwede, M., Schilling, B., Brandau, S., Weiss, S., & Jablonska, J. (2016) · International Journal of Cancer · doi:10.1002/ijc.29945 · Cited by 430
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Cham, C. M., Driessens, G., O'Keefe, J. P., & Gajewski, T. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200838289 · Cited by 388
Skobe, M., Hamberg, L. M., Hawighorst, T., Schirner, M., Wolf, G. L., Alitalo, K., & Detmar, M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61765-8 · Cited by 388
Krieg, C., Létourneau, S., Pantaleo, G., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002569107 · Cited by 380
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression
Mishalian, I., Bayuh, R., Levy, L., Zolotarov, L., Michaeli, J., & Fridlender, Z. G. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1476-9 · Cited by 356
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347 · cited 2×
“independently activated to eliminate melanoma cells that have significantly downregulated their MHC class I molecules (23, 38).”
BackgroundGaziel-Sovran, A., Segura, M. F., Di Micco, R., Collins, M. K., Hanniford, D., Vega-Saenz de Miera, E., Rakus, J. F., Dankert, J. F., Shang, S., Kerbel, R. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.027 · Cited by 343
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
Skin-Associated Lymphoid Tissues (SALT): Origins and Functions
Wayne Streilein, J. (1983) · Journal of Investigative Dermatology · doi:10.1038/jid.1983.4 · Cited by 318
Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2004) · Cancer · doi:10.1002/cncr.20057 · Cited by 314
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
Mechanisms and pathways of innate immune activation and regulation in health and cancer
Cui, J., Chen, Y., Wang, H. Y., & Wang, R.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.979640 · Cited by 309
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
Immunotherapy in melanoma: Recent advances and future directions
Franklin, C., Livingstone, E., Roesch, A., Schilling, B., & Schadendorf, D. (2017) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2016.07.145 · Cited by 278
Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 275
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155
Cai, X., Yin, Y., Li, N., Zhu, D., Zhang, J., Zhang, C.-Y., & Zen, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs044 · Cited by 260
Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98060 · Cited by 250
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 245
Nesbit, M., Schaider, H., Miller, T. H., & Herlyn, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6483 · Cited by 235
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Najjar, Y. G., Menk, A. V., Sander, C., Rao, U., Karunamurthy, A., Bhatia, R., Zhai, S., Kirkwood, J. M., & Delgoffe, G. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124989 · Cited by 233
Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function
Shaul, M. E., & Fridlender, Z. G. (2018) · The FEBS Journal · doi:10.1111/febs.14524 · Cited by 216
Strickland, I., Rhodes, L. E., Flanagan, B. F., & Friedmann, P. S. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12292156 · Cited by 198
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
Li, Z., Zhou, J., Zhang, J., Li, S., Wang, H., & Du, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32278 · Cited by 192
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells
Noman, M. Z., Buart, S., Romero, P., Ketari, S., Janji, B., Mari, B., Mami-Chouaib, F., & Chouaib, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1383 · Cited by 188
Han, Y., Guo, Q., Zhang, M., Chen, Z., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.111 · Cited by 187
Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., & Marincola, F. M. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00013 · Cited by 180
Distinct Functions of Neutrophil in Cancer and Its Regulation
Granot, Z., & Jablonska, J. (2015) · Mediators of Inflammation · doi:10.1155/2015/701067 · Cited by 179
Challacombe, J. M., Suhrbier, A., Parsons, P. G., Jones, B., Hampson, P., Kavanagh, D., Rainger, G. E., Morris, M., Lord, J. M., Le, T. T. T., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8123 · Cited by 177
Zhu, E. F., Gai, S. A., Opel, C. F., Kwan, B. H., Surana, R., Mihm, M. C., Kauke, M. J., Moynihan, K. D., Angelini, A., Williams, R. T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.004 · Cited by 177
Genetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171
Sabatino, M., Kim-Schulze, S., Panelli, M. C., Stroncek, D., Wang, E., Taback, B., Kim, D. W., DeRaffele, G., Pos, Z., Marincola, F. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1106 · Cited by 171
Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity
Huffaker, T. B., Hu, R., Runtsch, M. C., Bake, E., Chen, X., Zhao, J., Round, J. L., Baltimore, D., & O'Connell, R. M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.025 · Cited by 171
Manipulation of costimulatory signals to enhance antitumor T-cell responses
Allison, J. P., Hurwitz, A. A., & Leach, D. R. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80077-8 · Cited by 171
Metabolic rewiring in melanoma
Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W., & Ronai, Z. A. (2017) · Oncogene · doi:10.1038/onc.2016.198 · Cited by 171
Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 169
CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
Chikuma, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_61 · Cited by 168
Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 168
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 165
Not All Immune Checkpoints Are Created Equal
Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 161
Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
Kim, S.-H., Roszik, J., Grimm, E. A., & Ekmekçioglu, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00067 · Cited by 159
MicroRNAs and cancer epigenetics: a macrorevolution
Dávalos, V., & Esteller, M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333dcbb · Cited by 146
Harlin, H., Kuna, T. V., Peterson, A., Meng, Y., & Gajewski, T. F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0118-2 · Cited by 145
Melanoma-induced immunosuppression and its neutralization
Umansky, V., & Sevko, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.003 · Cited by 138
Tsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 137
The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells
Wehner, R., Dietze, K., Bachmann, M. P., & Schmitz, M. (2011) · Journal of Innate Immunity · doi:10.1159/000323923 · Cited by 134
Ziani, L., Safta, T. B., Gourbeix, J., Cavalcanti, A., Robert, C., Favre, G., Chouaïb, S., & Thiery, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15540 · Cited by 131
Dai, P., Wang, W., Yang, N., Serna‐Tamayo, C., Ricca, J. M., Zamarin, D., Shuman, S., Merghoub, T., Wolchok, J. D., & Deng, L. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal1713 · Cited by 128
Adenosine regulates CD8 T‐cell priming by inhibition of membrane‐proximal T‐cell receptor signalling
Linnemann, C., Schildberg, F. A., Schurich, A., Diehl, L., Hegenbarth, S. I., Endl, E., Lacher, S. K., Müller, C. E., Frey, J., Simeoni, L., et al. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03075.x · Cited by 124
Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity
Tucci, M., Mannavola, F., Passarelli, A. M., Stucci, L. S., Cives, M., & Silvestris, F. (2018) · Oncotarget · doi:10.18632/oncotarget.24846 · Cited by 122
Mechanisms of local immunosuppression in cutaneous melanoma
Polak, M. E., Borthwick, N., Gabriel, F. G., Johnson, P., Higgins, B., Hurren, J., McCormick, D., Jager, M. J., & Cree, I. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603763 · Cited by 117
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 117
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 115
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Hennart, B., Allorge, D., van Geel, N., Gele, M. V., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.982382 · Cited by 113
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 110
Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong, C. A., Botella, R., Galloway, T. H., Murray, N., Kramp, J.-P., Song, I. S., & Ansel, J. C. (1996) · PubMed · Cited by 109
Zhang, Y., & Ertl, H. C. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7818 · Cited by 107
miR-146a Controls Immune Response in the Melanoma Microenvironment
Mastroianni, J., Stickel, N., Andrlová, H., Hanke, K., Melchinger, W., Duquesne, S., Schmidt, D., Falk, M., Andrieux, G., Pfeifer, D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1397 · Cited by 102
Huang, Z. D., Gan, J., Long, Z., Guo, G., Shi, X., Wang, C., Zang, Y., Ding, Z., Chen, J., Zhang, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.009 · Cited by 99
Blache, C. A., Manuel, E. R., Kaltcheva, T. I., Wong, A. N., Ellenhorn, J. D. I., Blazar, B. R., & Diamond, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0193 · Cited by 98
Self-citationRole of miRNAs in Melanoma Metastasis
Gajos-Michniewicz, A., & Czyż, M. (2019) · Cancers · doi:10.3390/cancers11030326 · Cited by 95
Lahav, T. G., Adler, O., Zait, Y., Shani, O., Amer, M., Doron, H., Abramovitz, L., Yofe, I., Cohen, N., & Erez, N. (2019) · International Journal of Cancer · doi:10.1002/ijc.32521 · Cited by 92
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
Sylvester, R. J. (2010) · International Journal of Urology · doi:10.1111/j.1442-2042.2010.02678.x · Cited by 87
Eggermont, A. M. M., Suciu, S., Rutkowski, P. L., Kruit, W., Punt, C. J. A., Dummer, R., Salès, F., Keilholz, U., de Schaetzen, G., & Testori, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.014 · Cited by 86
Yuan, J. D., Ku, G. Y., Gallardo, H. F., Orlandi, F., Manukian, G., Rasalan, T. S., Xu, Y., Li, H., Vyas, S., Mu, Z., et al. (2009) · PubMed · Cited by 79
The role of nitric oxide in melanoma
Yarlagadda, K., Hassani, J., Foote, I. P., & Markowitz, J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.005 · Cited by 79
Zhou, J. Y., Yang, Y., Wang, W., Zhang, Y., Chen, Z., Hao, C., & Zhang, J. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.030 · Cited by 78
Telang, S., Rasku, M. A., Clem, A. L., Carter, K., Klarer, A. C., Badger, W. R., Milam, R. A., Rai, S. N., Pan, J., Gragg, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-515 · Cited by 76
CAR ‐T cell therapy in melanoma: A future success story?
Simon, B., & Uslu, U. (2018) · Experimental Dermatology · doi:10.1111/exd.13792 · Cited by 75
Wang, H., Ning, F., Liu, Z., Wu, L., Li, Z.-Q., Qi, Y.-F., Zhang, G., Wang, H., Cai, S., & Du, J. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1935-1 · Cited by 74
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606056 · Cited by 73
Manuel, E. R., Chen, J., D’Apuzzo, M., Lampa, M. G., Kaltcheva, T. I., Thompson, C. B., Ludwig, T., Chung, V. M., & Diamond, D. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0214 · Cited by 72
Self-citationLópez-Cobo, S., Pieper, N., Campos-Silva, C., García-Cuesta, E. M., Reyburn, H. T., Paschen, A., & Valés-Gómez, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1392426 · Cited by 71
Melanoma Immunotherapy: Next-Generation Biomarkers
Hogan, S. A., Levesque, M. P., & Cheng, P. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00178 · Cited by 70
Modulation of innate immunity in the tumor microenvironment
González-Gugel, E., Saxena, M., & Bhardwaj, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1859-9 · Cited by 69
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., Fernández, S., Shapiro, C. L., Otero, J. J., Timmers, C. D., et al. (2014) · Oncogene · doi:10.1038/onc.2014.294 · Cited by 66
Straten, P. T., Guldberg, P., Grønbæk, K., Hansen, M. R., Kirkin, A. F., Seremet, T., Zeuthen, J., & Becker, J. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.443 · Cited by 66
Sonner, J. K., Deumelandt, K., Ott, M., Thomé, C. M., Rauschenbach, K. J., Schulz, S., Munteanu, B., Mohapatra, S., Adam, I., Hofer, A.-C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240858 · Cited by 64
Farley, T., Mandava, N., Prall, F. R., & Carsky, C. (2008) · The Annals of Family Medicine · doi:10.1370/afm.857 · Cited by 60
Pro-tumor activities of macrophages in the progression of melanoma
Wang, H., Yang, L., Wang, D., Zhang, Q., & Zhang, L. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1312043 · Cited by 60
A Review of Exosomes and their Role in The Tumor Microenvironment and Host-Tumor "Macroenvironment"
Tung, K. H.-Y., Ernstoff, M. S., Allen, C. L., & Shu, S. L. (2019) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2019/1.1165 · Cited by 59
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 58
Cancer-Immune Equilibrium: Questions Unanswered
Bhatia, A., & Kumar, Y. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0065-8 · Cited by 55
The immune escape in melanoma: role of the impaired dendritic cell function
Tucci, M., Stucci, L. S., Passarelli, A. M., Giudice, G., Dammacco, F., & Silvestris, F. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.955851 · Cited by 55
Ding, Y., Zhang, S., & Qiao, J. (2018) · Medicine · doi:10.1097/md.0000000000011446 · Cited by 54
Arginine deprivation therapy for malignant melanoma
Kim, K., Yoon, Y., Frankel, A. E., Feun, & Ekmekcioglu (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s37350 · Cited by 50
Arts, N., Canè, S., Hennequart, M., Lamy, J., Bommer, G. T., den Eynde, B. J. V., & Plaen, E. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122517 · Cited by 50
miRNAs, Melanoma and Microenvironment: An Intricate Network
Romano, G., & Kwong, L. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112354 · Cited by 49
Bright, R., Coventry, B. J., Eardley-Harris, N., & Briggs, N. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000149 · Cited by 45
Freeman, A., Bridge, J. A., Maruthayanar, P., Overgaard, N. H., Jung, J., Simpson, F., Prow, T. W., Soyer, H. P., Frazer, I. H., Freeman, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110928 · Cited by 44
Melanoma and innate immunity – Active inflammation or just erroneous attraction?
Navarini, A. A., & Conrad, C. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.10.012 · Cited by 43
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 40
Austin, E., Mamalis, A., Ho, D. S., & Jagdeo, J. R. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1720-9 · Cited by 40
Tumor cells secreting IL-13 but not IL-13R 2 fusion protein have reduced tumorigenicity in vivo
Ma, H.-L. (2004) · International Immunology · doi:10.1093/intimm/dxh105 · Cited by 39
Chang, C. Y., Tai, J. A., Li, S., Nishikawa, T., & Kaneda, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9743 · Cited by 39
Izar, B., Joyce, C. E., Goff, S. L., Cho, N. L., Shah, P., Sharma, G., Li, J., Ibrahim, N., Gold, J. S., Hodi, F. S., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12513 · Cited by 39
Krähenbühl, L., Goldinger, S. M., Mangana, J., Kerl, K., Chevolet, I., Brochez, L., Horak, C. E., Levesque, M. P., Dummer, R., & Cheng, P. F. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.002 · Cited by 39
Li, Y., Zou, J.-M., Luo, C., Shu, Y., Luo, J., Qin, J., Wang, Y., Li, D., Wang, S., Chi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16084 · Cited by 37
Macrophage targeting contributes to the inhibitory effects of embelin on colitis-associated cancer
Wu, T., Dai, Y., Wang, W., Teng, G., Jiao, H., Shuai, X., Zhang, R., Zhao, P., & Qiao, L. (2016) · Oncotarget · doi:10.18632/oncotarget.6969 · Cited by 32
Innate immunity in cutaneous melanoma
Mignogna, C., Scali, E., Camastra, C., et al. (2017) · Clinical and Experimental Dermatology · doi:10.1111/ced.13023 · Cited by 31
Baldwin, G. C., Chung, G. Y., Kaslander, C., Esmail, T., Reisfeld, R. A., & Golde, D. W. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb04689.x · Cited by 29
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis
Caisová, V., Uher, O., Nedbalová, P., Jochmanová, I., Kvardová, K., Masáková, K., Krejčová, G., Paďouková, L., Chmelař, J., Kopecký, J., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.038 · Cited by 29
Role of interferon in melanoma: old hopes and new perspectives
Sanlorenzo, M., Vujic, I., Carnevale‐Schianca, F., Quaglino, P., Gammaitoni, L., Fierro, M. T., Aglietta, M., & Sangiolo, D. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1289169 · Cited by 25
New trends in antitumor vaccines in melanoma
Vásquez, M., Tenesaca, S., & Berraondo, P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.09 · Cited by 24
Grenier, J. M., Yeung, S. T., Qiu, Z., Jellison, E. R., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01993 · Cited by 24
Cassard, L., Cohen-Solal, J. F. G., Camilleri‐Broët, S., Fournier, E. M., Fridman, W. H., & Sautès‐Fridman, C. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0058-8 · Cited by 23
Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice
Roh, M. R., Zheng, Z., Kim, H. S., Jeung, H., Rha, S. Y., & Chung, K. Y. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835e7713 · Cited by 21
Gâta, V. A., Lisencu, C. I., Vlad, C. I., Piciu, D., Irimie, A., & Achimaș-Cădariu, P. (2017) · PubMed · Cited by 21
Kanatsios, S., Melbourne Melanoma Project, Suen, C. S. N. L. W., Cebon, J. S., & Gyorki, D. E. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25138 · Cited by 19
Palermo, B., Franzese, O., Donna, C. D., Panetta, M., Quintarelli, C., Sperduti, I., Gualtieri, N., Foddai, M. L., Proietti, E., Ferraresi, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465163 · Cited by 18
The good, the (not so) bad and the ugly of immune homeostasis in melanoma
Duarte, J. D. G., Woods, K., Andrews, M. C., & Behren, A. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12001 · Cited by 10
Campisano, S., Keon, S. M., Gazzaniga, S., Ruiz, M. S., Traian, M. M. D., Mordoh, J., & Wainstok, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.114 · Cited by 9
Cited by
Huang, A. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 571
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
The role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221
Zuo, B., Zhang, Y., Zhao, K., Wu, L., Qi, H., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 155
Metadata
- Authors
- Marzagalli, M., Ebelt, N. D., & Manuel, E. R.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 59
- Pages
- 236-250
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2967805215
- Cited by
- 345
- References
- 200
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.